Präneoplastische Läsionen und Vorstufen des Urothelkarzinoms

详细信息    查看全文

• 作者：Prof. Dr. R. Knüchel-Clarke ; N.T. Gaisa
• 关键词：Precancerous lesion ; Hyperplasia ; Intestinal metaplasia ; Squamous cell neoplasms ; Carcinoma in situ
• 刊名：Der Pathologe
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：37
• 期：1
• 页码：33-39
• 全文大小：1,062 KB
• 参考文献：1.Ahmad I, Barnetson RJ, Krishna NS (2008) Keratinizing squamous metaplasia of the bladder: a review. Urol Int 81:247–251CrossRef PubMed
  2.Amin MB, Trpkov K, Lopez-Beltran A, Grignon D, Members of the ISUP Immuno-histochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:20–34CrossRef
  3.Benson RC Jr, Swanson SK, Farrow GM (1984) Relationship of leukoplakia to urothelial malignancy. J Urol 131:507–511PubMed
  4.Broede A, Oll M, Maurer A, Siegert S, Stoerkel S, Golz R, Schwamborn K, Veeck J, Knuechel R, Gaisa NT (2015) Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear b-catenin-negative glandular tumours defines adenocarcinoma of the bladder. J Clin Pathol pii: jclinpath-2015-203144. doi:10.​1136/​jclinpath-2015-203144
  5.Cho KS, Seo JW, Park SJ, Lee YH, Choi YD, Cho NH, Yang SC, Hong SJ (2009) The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder. Urol Int 82:306–311CrossRef PubMed
  6.Clouston D, Lawrentschuk N (2013) Metaplastic conditions of the bladder. BJU Int 112:27–31CrossRef PubMed
  7.Epstein JI (2004) Urothelial hyperplasia. In: Eble JN, Sauter G, Epstein JI et al (Hrsg) Tumours of the urinary system and male genital organs. WHO classification of tumours. IARC Press, Lyon, S 111
  8.Gaisa NT, Braunschweig T, Reimer N, Bornemann J, Eltze E, Siegert S, Toma M, Villa L, Hartmann A, Knuechel R (2011) Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch 458:301–312
  9.Gaisa NT, Graham TA, McDonald SA, Cañadillas-Lopez S, Poulsom R, Heidenreich A, Jakse G, Tadrous PJ, Knuechel R, Wright NA (2011) The human urothelium consists of multiple clonal units, each maintained by a stem cell. J Pathol 225:163–171CrossRef PubMed
  10.Gaisa NT, Lindemann-Docter K (2015) Cytology in uropathological diagnostics. Pathologe 36:534–42. doi: 10.1007/s00292-015-0076-1CrossRef
  11.Glass RE, Coutsouvelis C, Sheikh-Fayyaz S, Chau K, Rosen L, Brenkert R, Slim F, Epelbaum F, Das K, Cocker RS (2015) Two-tiered subdivision of atypia on urine cytology can improve patient follow-up and optimize the utility of UroVysion. Cancer Cytopathol. doi:10.​1002/​cncy.​21630
  12.Gordetsky J, Epstein JI (2015) Intestinal metaplasia of the bladder with dysplasia: a risk factor for carcinoma? Histopathology 67:325–330CrossRef PubMed
  13.Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62:809–818PubMed
  14.Khan MS, Thornhill JA, Gaffney E, Loftus B, Butler MR (2002) Keratinizing squamous metaplasia of the bladder: natural history and rationalization of management based on a review of 54 years experience. Euro Urol 42:469–474
  15.Liang FX, Bosland MC, Huang H, Romih R, Baptiste S, Deng FM, Wu XR, Shapiro E, Sun TT (2005) Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. J Cell Biol 171:835–844PubMedCentral CrossRef
  16.Lindemann-Docter K, Knüchel-Clarke R (2008) Histopathology of urothelial carcinomas: crucial for patient management. Urologe A 47:627–636CrossRef
  17.Loeser A, Katzenberger T, Vergho DC, Kocot A, Burger M, Riedmiller H (2014) Frozen section analysis of ureteral margins in patients undergoing radical cystectomy for bladder cancer: differential impact of carcinoma in situ in the bladder on reliability and impact on tumour recurrence in the upper urinary tract. Urol Int 92:50–54
  18.Lopez-Beltran A, Marques RC, Montironi R, Reymundo C, Fonseca J, Cheng L (2015) Dysplasia and carcinoma in situ of the urinary bladder. Anal Quant Cytopathol Histpathol 37:29–38PubMed
  19.Mariappan P, Rai B, El-Mokadem I, Anderson CH, Lee H, Stewart S, Donat R (2015) Real-life Experience: early recurrence with Hexvix photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer. Urology 86:327–331CrossRef
  20.McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB (2001) Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 25:356–362CrossRef
  21.Molloy CJ, Laskin JD (1988) Effect of retinoid deficiency on keratin expression in mouse bladder. Exp Mol Pathol 49:128–140CrossRef PubMed
  22.Morton MJ, Zhang S, Lopez-Beltran A, MacLennan GT, Eble JN, Montironi R, Sung MT, Tan PH, Zheng S, Zhou H, Cheng L (2007) Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. Clin Cancer Res 13:6232–6236CrossRef PubMed
  23.Nese N, Gupta R, Bui MH, Amin MB (2009) Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw 7:48–57PubMed
  24.Sesterhenn IA (2004) Urothelial carcinoma in situ. In: Eble JN, Sauter G, Epstein JI et al (Hrsg) Tumours of the urinary system and male genital organs. WHO classification of tumours. IARC Press, Lyon, S 119–120
  25.Shin K, Lim A, Odegaard JI, Honeycutt JD, kawano S, Hsieh MH, Beachy PA (2014) Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol 16:469–478PubMedCentral CrossRef
  26.Smith AK, Hansel DE, Jones JS (2008) Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology 71:915–918CrossRef PubMed
  27.Stoehr R, Knuechel R, Boecker J, Blaszyk H, Schmitt R, Filbeck T, Hofstaedter F, Hartmann A (2002) Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab Invest 82:1553–1561CrossRef PubMed
  28.Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW (2013) Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol 182:449–459PubMedCentral CrossRef PubMed
  29.Sung MT, Lopez-Beltran A, Eble JN, MacLennan GT, Tan PH, Montironi R, Jones TD, Ulbright TM, Blair JE, Cheng L (2006) Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol 19:1395–1401CrossRef PubMed
  30.Tajima S, Koda K (2015) Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation. Int J Clin Exp Pathol 8:3288–3293PubMedCentral PubMed
  31.Van der Kwast TH, Zlotta AR, Fleshner N, Jewett M, Lopez-Beltran A, Montironi R (2008) Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology. Anal Quant Cytol Histol 30:309–315PubMed
  32.Van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, van der Kwast TH (2015) Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Mod Pathol 28:695–705CrossRef PubMed
  33.Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE (2009) Upper urinary tract recurrence after radical cystectomy for bladder cancer–who is at risk? J Urol 182:2632–2637CrossRef PubMed
  34.Young RH (2014) Nonneoplastic disorders of the urinary bladder. In: Bostwick DG, Cheng L (Hrsg) Urologic surgical pathology, 3. Aufl. Elsevier Saunders, Philadelphia, S 200–203
  35.Zaak D, Karl A, Stepp H, Tritschler S, Tilki D, Burger M, Knuechel R, Stief C (2007) Fluorescence cystoscopy at bladder cancer: present trials. Urologe A 46:1519–1527CrossRef PubMed
  36.Zhou H, Ro JY, Truong LD, Ayala AG, Shen SS (2014) Intraoperative frozen section evaluation of ureteral and urethral margins: studies of 203 consecutive radical cystoprostatectomy for men with bladder urothelial carcinoma. Am J Clin Exp Urol 2:156–160PubMedCentral CrossRef PubMed
  37.Zieger K, Marcussen N, Borre M, Ørntoft TF, Dyrskjøt L (2009) Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int J Cancer 125:2095–2103CrossRef PubMed
  
• 作者单位：Prof. Dr. R. Knüchel-Clarke (1)
  N.T. Gaisa (1)
  
  1. Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1963

文摘

As even a mere thickening of the urothelium can harbor genetic changes identical to that of low grade papillary urothelial tumors, it is not always possible to clearly recognize a precursor lesion of urothelial carcinoma by routine histological diagnostics. Complementary immunohistochemical and molecular diagnostic methods assist the recognition of these entities. These methods especially help to identify clinically important genetically unstable cells as the hallmark of carcinoma in situ (CIS). Little is known about the clinical significance of the morphological subtypes of CIS, which range from large cell to micropapillary variants. For a better understanding of special types of bladder cancer (e.g. adenocarcinoma and squamous cell carcinoma), it seems to be important to define the phenotype and the molecular pattern of non-urothelial lesions, such as intestinal metaplasia and squamous metaplasia, better and more precisely.